BJC Open article

British Journal of Cancer (2002) 87, 49–53. doi:10.1038/sj.bjc.6600370 www.bjcancer.com
Published online 25 June 2002

Aspirin and lung cancer in women

A Akhmedkhanov1,2, P Toniolo1,2, A Zeleniuch-Jacquotte2, K L Koenig2 and R E Shore2

  1. 1Department of Obstetrics and Gynecology, New York University School of Medicine, 550 First Avenue, NBV-9E2, New York, NY 10016, USA
  2. 2Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA

Correspondence: Dr A Akhmedkhanov, E-mail: akhmea01@med.nyu.edu

Received 17 January 2002; Revised 18 April 2002; Accepted 19 April 2002



The association between aspirin use and lung cancer risk in women was examined in a case–control study nested in the New York University Women's Health Study, a large cohort in New York. Case subjects were all the 81 incident lung cancer cases who had provided information about aspirin use at enrollment and during the 1994–1996 follow up. Ten controls per case were randomly selected from among study participants who matched a case by age, menopausal status, and dates of enrollment and follow-up. Relative to no aspirin use, the odds ratio for lung cancer (all histological sub-types combined) among subjects who reported aspirin use three or more times per week for at least 6 months was 0.66 (95% confidence interval 0.34–1.28), after adjustment for smoking and education. A stronger inverse association was observed in analyses restricted to non-small cell lung cancer (adjusted odds ratio 0.39, 95% confidence interval 0.16–0.96). These results suggest that regular aspirin use might be inversely associated with risk of lung cancer in women, particularly the non-small cell sub-type.


aspirin; lung neoplasms, female; case–control study; epidemiology